What one share of Corcept Therapeutics holds
We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.
Corcept Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $7.04 |
|---|---|
| Profit | $0.46 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $0.91 |
| Cash and investments | $5.04 |
| Book value | $6.53 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $0.00 | −$0.38 | — | — | — | $0.42 |
| 2010 | — | −$0.38 | — | — | — | $0.29 |
| 2011 | — | −$0.39 | $0.00 | −$0.33 | — | $0.41 |
| 2012 | $0.04 | −$0.41 | $0.00 | −$0.39 | — | $0.62 |
| 2013 | $0.10 | −$0.46 | $0.00 | −$0.37 | $0.00 | $0.21 |
| 2014 | $0.26 | −$0.31 | $0.00 | −$0.27 | — | −$0.03 |
| 2015 | $0.47 | −$0.06 | $0.00 | $0.03 | — | $0.17 |
| 2016 | $0.70 | $0.07 | $0.00 | $0.16 | — | $0.37 |
| 2017 | $1.28 | $1.04 | $0.00 | $0.49 | — | $1.66 |
| 2018 | $1.98 | $0.60 | $0.00 | $0.91 | — | $2.40 |
| 2019 | $2.50 | $0.77 | $0.01 | $1.10 | — | $3.24 |
| 2020 | $2.85 | $0.85 | $0.01 | $1.21 | — | $4.48 |
| 2021 | $2.91 | $0.89 | $0.00 | $1.33 | — | $3.55 |
| 2022 | $3.47 | $0.87 | $0.00 | $1.03 | — | $4.65 |
| 2023 | $4.32 | $0.94 | $0.00 | $1.13 | — | $4.90 |
| 2024 | $5.95 | $1.23 | $0.02 | $1.73 | — | $6.47 |
| 2025 | $6.35 | $0.82 | $0.00 | $1.18 | — | $6.11 |
Common questions about Corcept Therapeutics
How much does one share of Corcept Therapeutics earn?
Over the last 12 months, each share of Corcept Therapeutics earned $0.46 of profit on $7.04 of sales, keeping about 7¢ of every $1 (profit margin).
Does Corcept Therapeutics pay a dividend?
Corcept Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Corcept Therapeutics’s book value per share?
Corcept Therapeutics’s book value is $6.53 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Corcept Therapeutics have?
Each share of Corcept Therapeutics has $5.04 of cash and investments, as of June 30, 2026.
What is Corcept Therapeutics’s free cash flow per share?
$0.91 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Corcept Therapeutics bought back shares?
Corcept Therapeutics’s share count rose about 126% from 2009 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.